Letter to the Editor: Statins and Reduced Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B
- PMID: 31858599
- DOI: 10.1002/hep.31080
Letter to the Editor: Statins and Reduced Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B
Comment in
-
Reply.Hepatology. 2020 Jun;71(6):2174-2175. doi: 10.1002/hep.31079. Hepatology. 2020. PMID: 31860747 No abstract available.
Comment on
-
Statin Use and the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B.Hepatology. 2020 Jun;71(6):2023-2032. doi: 10.1002/hep.30973. Epub 2020 Feb 14. Hepatology. 2020. PMID: 31556128
References
REFERENCES
-
- Goh MJ, Sinn DH, Kim S, Woo SY, Cho H, Kang W, et al. Statin use and the risk of hepatocellular carcinoma in patients with chronic hepatitis B. Hepatology 2019 Sept 25. https://doi.org/10.1002/hep.30973. [Epub ahead of print]
-
- Singh S, Singh PP, Singh AG, Murad MH, McWilliams RR, Chari ST. Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis. Am J Gastroenterol 2013;108:510-519.
-
- Bravi F, Bosetti C, Tavani A, Bagnardi V, Gallus S, Negri E, et al. Coffee drinking and hepatocellular carcinoma risk: a meta-analysis. Hepatology 2007;46:430-435.
-
- Choi J, Kim HJ, Lee J, Cho S, Ko MJ, Lim YS. Risk of hepatocellular carcinoma in patients treated with entecavir vs tenofovir for chronic hepatitis B: a Korean nationwide cohort study. JAMA Oncol 2019;5:30-36.
-
- World Health Organization. Guidelines for the Prevention, Care and Treatment of Persons With Chronic Hepatitis B Infection. Geneva, Switzerland: World Health Organization; 2015.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
